Accordingly, major approaches to AD drug development over the past two decades have focused on lowering Aβ - for example, by inhibition of BACE or γ-secretase, or by the use of therapeutic antibodies to neutralize or enhance clearance of Aβ. This evidence concerns the gene BACE1 and Alzheimer disease.